Table 1 Characteristics of patients... | American Society of Hematology

Table 1

Characteristics of patients treated with dasatinib or imatinib

Patient no.	Age, y	Sex	Hematologic disease	Drug treatment, mg/d	Disease status	BCR-ABL, %	Platelets, g/L
1	73	Male	BC-CML	D, 100	CHR	2	163
2	41	Female	Ph⁺ ALL	D, 70 × 2	CHR	Undetectable	311
3	78	Male	AP-CML	D, 100	CHR	28	120
4	58	Female	CML	D, 70 × 2	CHR	20	219
5	56	Female	CML	100	CHR	76	305
6	54	Male	Ph⁺ ALL	D, 70 × 2	CHR	0.09	132
7	21	Female	CML	I, 400	CHR	Undetectable	160
8	38	Male	CML	I, 400	CHR	1.2	238
9	68	Female	CML	I, 600	CHR	Undetectable	163

Patient no.	Age, y	Sex	Hematologic disease	Drug treatment, mg/d	Disease status	BCR-ABL, %	Platelets, g/L
1	73	Male	BC-CML	D, 100	CHR	2	163
2	41	Female	Ph⁺ ALL	D, 70 × 2	CHR	Undetectable	311
3	78	Male	AP-CML	D, 100	CHR	28	120
4	58	Female	CML	D, 70 × 2	CHR	20	219
5	56	Female	CML	100	CHR	76	305
6	54	Male	Ph⁺ ALL	D, 70 × 2	CHR	0.09	132
7	21	Female	CML	I, 400	CHR	Undetectable	160
8	38	Male	CML	I, 400	CHR	1.2	238
9	68	Female	CML	I, 600	CHR	Undetectable	163

BC indicates blast crisis; Ph⁺, Philadelphia chromosome–positive; D, dasanitib, I, imatinib; AP, accelerated phase; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; and CHR, complete hematological response (normalization of the peripheral blood counts and differential, absence of peripheral blasts, and disappearance of all signs and symptoms of the disease).

View Large

This Feature Is Available To Subscribers Only